{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:06Z","timestamp":1772165766023,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Fujian Province grants","award":["2023J01674"],"award-info":[{"award-number":["2023J01674"]}]},{"name":"Fujian province medical \"Create Double High\" construction funding","award":["Fujian Health Medical Policy [2021] No. 76"],"award-info":[{"award-number":["Fujian Health Medical Policy [2021] No. 76"]}]},{"name":"the Excellent Young Scholars Cultivation Project of Fujian Medical University Union Hospital","award":["2022XH022"],"award-info":[{"award-number":["2022XH022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13840-7","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:53:26Z","timestamp":1741863206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Qi-Chen","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Ning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Bin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-He","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru-Hong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Long","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"3","key":"13840_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"38","key":"13840_CR2","doi-asserted-by":"publisher","first-page":"13692","DOI":"10.3748\/wjg.v20.i38.13692","volume":"20","author":"JJW Tegels","year":"2014","unstructured":"Tegels JJW, De Maat MFG, Hulsew\u00e9 KWE, Hoofwijk AGM, Stoot JHMB. Improving the outcomes in gastric cancer surgery. World J Gastroenterol. 2014;20(38):13692\u2013704. https:\/\/doi.org\/10.3748\/wjg.v20.i38.13692.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"13840_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(10)70070-X.","journal-title":"Lancet Oncol"},{"key":"13840_CR4","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1-21. https:\/\/doi.org\/10.1007\/s10120-020-01042-y.","DOI":"10.1007\/s10120-020-01042-y"},{"issue":"10","key":"13840_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","volume":"14","author":"JA Ajani","year":"2016","unstructured":"Ajani JA, D\u2019Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(10):1286\u2013312. https:\/\/doi.org\/10.6004\/jnccn.2016.0137.","journal-title":"J Natl Compr Canc Netw"},{"key":"13840_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.01.106","volume":"112","author":"MP Lutz","year":"2019","unstructured":"Lutz MP, Zalcberg JR, Ducreux M, et al. The 4th St. Gallen EORTC gastrointestinal cancer conference: controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer. 2019;112:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2019.01.106.","journal-title":"Eur J Cancer"},{"key":"13840_CR7","doi-asserted-by":"publisher","unstructured":"National Health Commission Of The People\u2019s Republic Of China null. Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version). Chin J Cancer Res. 2019;31(5):707\u2013737. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.05.01.","DOI":"10.21147\/j.issn.1000-9604.2019.05.01"},{"issue":"1","key":"13840_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"issue":"8","key":"13840_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7.","journal-title":"Lancet Oncol"},{"key":"13840_CR10","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; International Agency for Research on Cancer; World Health Organization. Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC; 1994."},{"issue":"10","key":"13840_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/cncr.24253","volume":"115","author":"D Marrelli","year":"2009","unstructured":"Marrelli D, Pedrazzani C, Berardi A, et al. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115(10):2071\u201380. https:\/\/doi.org\/10.1002\/cncr.24253.","journal-title":"Cancer"},{"issue":"3","key":"13840_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(06)70586-1","volume":"7","author":"G Meimarakis","year":"2006","unstructured":"Meimarakis G, Winter H, Assmann I, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7(3):211\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(06)70586-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"13840_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jso.24977","volume":"117","author":"SS Nishizuka","year":"2018","unstructured":"Nishizuka SS, Tamura G, Nakatochi M, et al. Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy. J Surg Oncol. 2018;117(5):947\u201356. https:\/\/doi.org\/10.1002\/jso.24977.","journal-title":"J Surg Oncol"},{"issue":"4","key":"13840_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00280-012-1944-5","volume":"70","author":"IK Choi","year":"2012","unstructured":"Choi IK, Sung HJ, Lee JH, Kim JS, Seo JH. The relationship between Helicobacter pylori infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer. Cancer Chemother Pharmacol. 2012;70(4):555\u20138. https:\/\/doi.org\/10.1007\/s00280-012-1944-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"13840_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/hel.12120","volume":"19","author":"X Zhou","year":"2014","unstructured":"Zhou X, Su J, Zhu L, Zhang G. Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter. 2014;19(3):174\u201381. https:\/\/doi.org\/10.1111\/hel.12120.","journal-title":"Helicobacter"},{"issue":"4","key":"13840_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.26081","volume":"130","author":"SY Kang","year":"2012","unstructured":"Kang SY, Han JH, Ahn MS, et al. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer. 2012;130(4):948\u201358. https:\/\/doi.org\/10.1002\/ijc.26081.","journal-title":"Int J Cancer"},{"key":"13840_CR17","doi-asserted-by":"publisher","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167\u2013192. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","DOI":"10.6004\/jnccn.2022.0008"},{"issue":"5","key":"13840_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/annonc\/mdp464","volume":"21","author":"W Koizumi","year":"2010","unstructured":"Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21(5):1001\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdp464.","journal-title":"Ann Oncol"},{"issue":"2","key":"13840_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00432-013-1563-5","volume":"140","author":"W Koizumi","year":"2014","unstructured":"Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319\u201328. https:\/\/doi.org\/10.1007\/s00432-013-1563-5.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"13840_CR20","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6602573","volume":"92","author":"F De Vita","year":"2005","unstructured":"De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92(9):1644\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6602573.","journal-title":"Br J Cancer"},{"issue":"8","key":"13840_CR21","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1007\/s00464-023-10084-z","volume":"37","author":"HL Zheng","year":"2023","unstructured":"Zheng HL, Shen LL, Xu BB, et al. Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy: a study of real-world data. Surg Endosc. 2023;37(8):6288\u201397. https:\/\/doi.org\/10.1007\/s00464-023-10084-z.","journal-title":"Surg Endosc"},{"key":"13840_CR22","doi-asserted-by":"publisher","unstructured":"Doescher J, Veit JA, Hoffmann TK. [The 8th edition of the AJCC Cancer Staging Manual\u202f: Updates in otorhinolaryngology, head and neck surgery]. HNO. 2017;65(12):956\u2013961. https:\/\/doi.org\/10.1007\/s00106-017-0391-3.","DOI":"10.1007\/s00106-017-0391-3"},{"issue":"10","key":"13840_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","volume":"20","author":"MF Dixon","year":"1996","unstructured":"Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161\u201381. https:\/\/doi.org\/10.1097\/00000478-199610000-00001.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"13840_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","volume":"253","author":"K Becker","year":"2011","unstructured":"Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after Neoadjuvant chemotherapy in gastric adenocarcinomas: A Summary of 480 Cases. Ann Surg. 2011;253(5):934\u20139. https:\/\/doi.org\/10.1097\/SLA.0b013e318216f449.","journal-title":"Ann Surg"},{"issue":"9","key":"13840_CR25","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","volume":"24","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, Chen HC, Wang X, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24(9):2679\u201387. https:\/\/doi.org\/10.1245\/s10434-017-5838-y.","journal-title":"Ann Surg Oncol"},{"issue":"446","key":"13840_CR26","doi-asserted-by":"publisher","first-page":"496e509","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496e509.","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"13840_CR27","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.18632\/oncotarget.6641","volume":"7","author":"WL Fang","year":"2016","unstructured":"Fang WL, Huang KH, Lan YT, et al. Mutations in PI3K\/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. Oncotarget. 2016;7(5):6201\u201320. https:\/\/doi.org\/10.18632\/oncotarget.6641.","journal-title":"Oncotarget"},{"issue":"3","key":"13840_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1074\/jbc.M806981200","volume":"284","author":"M Nakayama","year":"2009","unstructured":"Nakayama M, Hisatsune J, Yamasaki E, et al. Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K\/Akt signaling pathway. J Biol Chem. 2009;284(3):1612\u20139. https:\/\/doi.org\/10.1074\/jbc.M806981200.","journal-title":"J Biol Chem"},{"key":"13840_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fcimb.2017.00417","volume":"7","author":"N Li","year":"2017","unstructured":"Li N, Tang B, Jia YP, et al. Helicobacter pylori CagA protein negatively regulates autophagy and promotes inflammatory Response via c-Met-PI3K\/Akt-mTOR signaling pathway. Front Cell Infect Microbiol. 2017;7:417. https:\/\/doi.org\/10.3389\/fcimb.2017.00417.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"13840_CR30","doi-asserted-by":"publisher","first-page":"e845","DOI":"10.1634\/theoncologist.2018-0742","volume":"24","author":"WL Fang","year":"2019","unstructured":"Fang WL, Huang KH, Chang SC, et al. Comparison of the clinicopathological characteristics and genetic alterations between patients with gastric cancer with or without helicobacter pylori infection. Oncologist. 2019;24(9):e845\u201353. https:\/\/doi.org\/10.1634\/theoncologist.2018-0742.","journal-title":"Oncologist"},{"issue":"12","key":"13840_CR31","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.4049\/jimmunol.169.12.6977","volume":"169","author":"AA Akhiani","year":"2002","unstructured":"Akhiani AA, Pappo J, Kabok Z, et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol. 2002;169(12):6977\u201384. https:\/\/doi.org\/10.4049\/jimmunol.169.12.6977.","journal-title":"J Immunol"},{"issue":"3","key":"13840_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/s0016-5085(98)70531-1","volume":"114","author":"KB Bamford","year":"1998","unstructured":"Bamford KB, Fan X, Crowe SE, et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology. 1998;114(3):482\u201392. https:\/\/doi.org\/10.1016\/s0016-5085(98)70531-1.","journal-title":"Gastroenterology"},{"issue":"8","key":"13840_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747\u201395. https:\/\/doi.org\/10.1002\/cac2.12193.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"13840_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4174\/jkss.2012.83.4.203","volume":"83","author":"H Hur","year":"2012","unstructured":"Hur H, Lee SR, Xuan Y, et al. The Effects of Helicobacter pylori on the prognosis of patients with curatively resected gastric cancers in a population with high infection rate. J Korean Surg Soc. 2012;83(4):203\u201311. https:\/\/doi.org\/10.4174\/jkss.2012.83.4.203.","journal-title":"J Korean Surg Soc"},{"issue":"12","key":"13840_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(14)70473-5.","journal-title":"Lancet Oncol"},{"issue":"6","key":"13840_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10120-018-0831-0","volume":"21","author":"Z Cai","year":"2018","unstructured":"Cai Z, Yin Y, Yin Y, et al. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis. Gastric Cancer. 2018;21(6):1031\u201340. https:\/\/doi.org\/10.1007\/s10120-018-0831-0.","journal-title":"Gastric Cancer"},{"issue":"24","key":"13840_CR37","doi-asserted-by":"publisher","first-page":"39673","DOI":"10.18632\/oncotarget.17784","volume":"8","author":"J Sun","year":"2017","unstructured":"Sun J, Ren Z, Sun X, Hou H, Li K, Ge Q. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis. Oncotarget. 2017;8(24):39673\u201382. https:\/\/doi.org\/10.18632\/oncotarget.17784.","journal-title":"Oncotarget"},{"issue":"2","key":"13840_CR38","doi-asserted-by":"publisher","first-page":"e90155","DOI":"10.1371\/journal.pone.0090155","volume":"9","author":"F Endo","year":"2014","unstructured":"Endo F, Nishizuka SS, Kume K, et al. A compensatory role of NF-\u03baB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One. 2014;9(2):e90155. https:\/\/doi.org\/10.1371\/journal.pone.0090155.","journal-title":"PLoS One"},{"issue":"6","key":"13840_CR39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1128\/MCB.01136-10","volume":"31","author":"AK Frank","year":"2011","unstructured":"Frank AK, Leu JIJ, Zhou Y, et al. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol. 2011;31(6):1201\u201313. https:\/\/doi.org\/10.1128\/MCB.01136-10.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"13840_CR40","doi-asserted-by":"publisher","first-page":"e43236","DOI":"10.1371\/journal.pone.0043236","volume":"7","author":"K Ishida","year":"2012","unstructured":"Ishida K, Nishizuka SS, Chiba T, et al. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One. 2012;7(8):e43236. https:\/\/doi.org\/10.1371\/journal.pone.0043236.","journal-title":"PLoS One"},{"key":"13840_CR41","doi-asserted-by":"publisher","first-page":"25895","DOI":"10.1038\/srep25895","volume":"6","author":"K Kume","year":"2016","unstructured":"Kume K, Ikeda M, Miura S, et al. \u03b1-Amanitin restrains cancer relapse from drug-tolerant cell subpopulations via TAF15. Sci Rep. 2016;6:25895. https:\/\/doi.org\/10.1038\/srep25895.","journal-title":"Sci Rep"},{"issue":"50","key":"13840_CR42","doi-asserted-by":"publisher","first-page":"21418","DOI":"10.1073\/pnas.1010153107","volume":"107","author":"DJ Kim","year":"2010","unstructured":"Kim DJ, Park KS, Kim JH, et al. Helicobacter pylori proinflammatory protein up-regulates NF-kappaB as a cell-translocating Ser\/Thr kinase. Proc Natl Acad Sci U S A. 2010;107(50):21418\u201323. https:\/\/doi.org\/10.1073\/pnas.1010153107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"13840_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nm1566","volume":"13","author":"Y Matsumoto","year":"2007","unstructured":"Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13(4):470\u20136. https:\/\/doi.org\/10.1038\/nm1566.","journal-title":"Nat Med"},{"issue":"4","key":"13840_CR44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.coi.2010.06.001","volume":"22","author":"H Marusawa","year":"2010","unstructured":"Marusawa H, Chiba T. Helicobacter pylori-induced activation-induced cytidine deaminase expression and carcinogenesis. Curr Opin Immunol. 2010;22(4):442\u20137. https:\/\/doi.org\/10.1016\/j.coi.2010.06.001.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"13840_CR45","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3892\/ol.2014.1963","volume":"7","author":"J Zhang","year":"2014","unstructured":"Zhang J, Guo H, Zhu JS, Yang YC, Chen WX, Chen NW. Inhibition of phosphoinositide 3-kinase\/Akt pathway decreases hypoxia inducible factor-1\u03b1 expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells. Oncol Lett. 2014;7(5):1401\u20138. https:\/\/doi.org\/10.3892\/ol.2014.1963.","journal-title":"Oncol Lett"},{"issue":"2","key":"13840_CR46","doi-asserted-by":"publisher","first-page":"e2306230","DOI":"10.1002\/advs.202306230","volume":"11","author":"X Song","year":"2024","unstructured":"Song X, Cai H, Shi Z, et al. Enzyme-Responsive Branched Glycopolymer-Based Nanoassembly for Co-Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer. Adv Sci (Weinh). 2024;11(2):e2306230. https:\/\/doi.org\/10.1002\/advs.202306230.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"13840_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1053\/gast.2002.34751","volume":"123","author":"JJ Kim","year":"2002","unstructured":"Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology. 2002;123(2):542\u201353. https:\/\/doi.org\/10.1053\/gast.2002.34751.","journal-title":"Gastroenterology"},{"issue":"1","key":"13840_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5114\/wo.2021.104939","volume":"25","author":"C Zepeda-Najar","year":"2021","unstructured":"Zepeda-Najar C, Palacios-Astudillo RX, Ch\u00e1vez-Hern\u00e1ndez JD, Lino-Silva LS, Salcedo-Hern\u00e1ndez RA. Prognostic impact of microsatellite instability in gastric cancer. Contemp Oncol (Pozn). 2021;25(1):68\u201371. https:\/\/doi.org\/10.5114\/wo.2021.104939.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"3","key":"13840_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bjs.10663","volume":"105","author":"K Polom","year":"2018","unstructured":"Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105(3):159\u201367. https:\/\/doi.org\/10.1002\/bjs.10663.","journal-title":"Br J Surg"},{"issue":"22","key":"13840_CR50","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00018-018-2906-9","volume":"75","author":"M Ratti","year":"2018","unstructured":"Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75(22):4151\u201362. https:\/\/doi.org\/10.1007\/s00018-018-2906-9.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"13840_CR51","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/bjs.1800820627","volume":"82","author":"WJ Lee","year":"1995","unstructured":"Lee WJ, Lin JT, Shun CT, et al. Comparison between resectable gastric adenocarcinomas seropositive and seronegative for Helicobacter pylori. Br J Surg. 1995;82(6):802\u20135. https:\/\/doi.org\/10.1002\/bjs.1800820627.","journal-title":"Br J Surg"},{"issue":"3","key":"13840_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00004836-199510000-00007","volume":"21","author":"WJ Lee","year":"1995","unstructured":"Lee WJ, Lin JT, Lee WC, et al. Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas. J Clin Gastroenterol. 1995;21(3):203\u20137. https:\/\/doi.org\/10.1097\/00004836-199510000-00007.","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"13840_CR53","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1053\/j.gastro.2007.03.088","volume":"132","author":"M Hobsley","year":"2007","unstructured":"Hobsley M, Tovey FI, Holton J. Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology. 2007;132(5):2076. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.088.","journal-title":"Gastroenterology"},{"issue":"4","key":"13840_CR54","doi-asserted-by":"publisher","first-page":"e225557","DOI":"10.1001\/jamanetworkopen.2022.5557","volume":"5","author":"JX Lin","year":"2022","unstructured":"Lin JX, Tang YH, Lin GJ, et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after Neoadjuvant chemotherapy. JAMA Netw Open. 2022;5(4):e225557. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.5557.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"13840_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer."},{"issue":"10184","key":"13840_CR56","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"17","key":"13840_CR57","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3390\/jcm11175086","volume":"11","author":"M Shatila","year":"2022","unstructured":"Shatila M, Thomas AS. Current and future perspectives in the diagnosis and management of helicobacter pylori Infection. J Clin Med. 2022;11(17):5086. https:\/\/doi.org\/10.3390\/jcm11175086.","journal-title":"J Clin Med"},{"issue":"2","key":"13840_CR58","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/diagnostics12020508","volume":"12","author":"AI Cardos","year":"2022","unstructured":"Cardos AI, Maghiar A, Zaha DC, et al. Evolution of diagnostic methods for helicobacter pylori infections: from traditional tests to high technology, advanced sensitivity and discrimination tools. Diagnostics (Basel). 2022;12(2):508. https:\/\/doi.org\/10.3390\/diagnostics12020508.","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"13840_CR59","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.3747\/co.20.1417","volume":"20","author":"F Wang","year":"2013","unstructured":"Wang F, Sun GP, Zou YF, et al. Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol. 2013;20(5):e388-395. https:\/\/doi.org\/10.3747\/co.20.1417.","journal-title":"Curr Oncol"},{"issue":"6","key":"13840_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/1319-3767.103428","volume":"18","author":"S Shukla","year":"2012","unstructured":"Shukla S, Pujani M, Agarwal A, Pujani M, Rohtagi A. Correlation of serology with morphological changes in gastric biopsy in Helicobacter pylori infection and evaluation of immunohistochemistry for H. pylori identification. Saudi J Gastroenterol. 2012;18(6):369\u201374. https:\/\/doi.org\/10.4103\/1319-3767.103428.","journal-title":"Saudi J Gastroenterol"},{"key":"13840_CR61","first-page":"69","volume":"5","author":"IS Pity","year":"2011","unstructured":"Pity IS, Baizeed AM. Identification of helicobacter pylori in gastric biopsies of patients with chronic gastritis: histopathological and immunohistochemical study. Duhok Med J. 2011;5:69\u201377.","journal-title":"Duhok Med J"},{"issue":"1","key":"13840_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5334\/aogh.2570","volume":"85","author":"MA Abd Rahim","year":"2019","unstructured":"Abd Rahim MA, Johani FH, Shah SA, Hassan MR, Abdul Manaf MR. 13C-Urea breath test accuracy for helicobacter pylori infection in the Asian population: A meta-analysis. Ann Glob Health. 2019;85(1):110. https:\/\/doi.org\/10.5334\/aogh.2570.","journal-title":"Ann Glob Health"},{"key":"13840_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-0716-1302-3_2","volume":"2283","author":"A O\u2019Connor","year":"2021","unstructured":"O\u2019Connor A. The Urea breath test for the noninvasive detection of helicobacter pylori. Methods Mol Biol. 2021;2283:15\u201320. https:\/\/doi.org\/10.1007\/978-1-0716-1302-3_2.","journal-title":"Methods Mol Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13840-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13840-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13840-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:53:38Z","timestamp":1741863218000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13840-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13840"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13840-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4498174\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol has been reviewed and approved by the Ethics Committees of Fujian Medical University Union Hospital, Fujian Medical University Affiliated Zhangzhou Hospital, and Qinghai University Affiliated Hospital (Number of IRB: 2024KY090), in accordance with the ethical regulations for biomedical research in the People's Republic of China. All participants from the three hospitals signed written informed consent forms prior to their inclusion in the study. The consent forms clearly included the following elements: 1) the purpose, methods, and expected duration of the study; 2) foreseeable risks and potential benefits; 3) the voluntary nature of participation and the right to withdraw unconditionally; and 4) data anonymization and confidentiality measures. For patients unable to provide direct consent (such as those in a coma), we obtained proxy consent from legal guardians or close relatives. All patient data are stored in a de-identified coded format, with access to the original data restricted to core members of the research team. When the study results are published, no identifiable personal information will be included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}